1. 117Investigation of the transmural APD properties of scar borderzone in patients undergoing ventricular tachycardia ablation. (20th June 2017) Authors: Srinivasan, NT.; Orini, M.; Providencia, R.; Martin, C.; Dhinoja, M.; Hunter, R.; Lowe, MD.; Khan, F.; Taggart, PD.; Schilling, RJ.; Lambiase, PD. Journal: Europace Issue: Volume 19(2017)Supplement 3 Page Start: iii12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 153 Acquired Resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-Mutant lung cancer among Hispanics (CLICaP). (September 2015) Authors: Zorrilla, A. Cardona; Arrieta, O.; Rojas, L.; Corrales, L.; Vargas, C.; Carranza, H.; Cuello, M.; Martin, C.; Rosell, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors. (December 2022) Authors: Oh, D.; Henry, J.; Baranda, J.C.; Dumbrava, E.E.; Cohen, E.; Eskew, J.D.; Belani, R.; McCaigue, J.; Namini, H.; Martin, C.; Murphy, A.; Ostertag, E.; Coronella, J.; Shedlock, D.; Rodriguez Rivera, I.I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM). (December 2022) Authors: Kocoglu, M.H.; Asch, A.; Ramakrishnan, A.; Bachier, C.; Martin, T.; Rodriguez, T.; McArthur, K.; Martin, C.; Namini, H.; Ostertag, E.; Spear, M.; Christie, E.; Belani, R.; Zhang, M.; Cranert, S.; Coronella, J.; Shedlock, D.; Costello, C. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A recurrent mutation in DEPDC5 predisposes to focal epilepsies in the French‐Canadian population. (27th November 2013) Authors: Martin, C.; Meloche, C.; Rioux, M.‐F.; Nguyen, D.K.; Carmant, L.; Andermann, E.; Gravel, M.; Cossette, P. Journal: Clinical genetics Issue: Volume 86:Number 6(2014:Dec.) Page Start: 570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A systematic functional activity characterization of the most frequent GOF and LOF PSCK9 variants. (August 2018) Authors: Vicente, A. Benito; Uribe, K.B.; Chemello, K.; Garcia, U Galicia; Alonso, R.; Lambert, G.; Martin, C. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AB0843-HPR To lead and to follow - experiences from guiding people with rheumatoid arthritis to increased physical activity. the para 2010 study. (23rd January 2014) Authors: Nessen, T.; Opava, C.; Martin, C.; Demmelmaier, I. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A1097 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats. Issue 2 (February 2015) Authors: Etxebarria, A.; Benito-Vicente, A.; Stef, M.; Ostolaza, H.; Palacios, L.; Martin, C. Journal: Atherosclerosis Issue: Volume 238:Issue 2(2015) Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Adcitmer®, a new CD56‐targeting monomethyl auristatin E‐conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. (1st February 2022) Authors: Esnault, C.; Leblond, V.; Martin, C.; Desgranges, A.; Baltus, C.B.; Aubrey, N.; Lakhrif, Z.; Lajoie, L.; Lantier, L.; Clémenceau, B.; Sarma, B.; Schrama, J.; Houben, R.; Schrama, D.; Hesbacher, S.; Gouilleux‐Gruart, V.; Feng, Y.; Dimitrov, D.; Guyétant, S.; Berthon, P. Journal: British journal of dermatology Issue: Volume 186:Number 2(2022) Page Start: 295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Adcitmer®, a new CD56‐targeting monomethyl auristatin E‐conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. (2nd November 2021) Authors: Esnault, C.; Leblond, V.; Martin, C.; Desgranges, A.; Baltus, C.B.; Aubrey, N.; Lakhrif, Z.; Lajoie, L.; Lantier, L.; Clémenceau, B.; Sarma, B.; Schrama, J.; Houben, R.; Schrama, D.; Hesbacher, S.; Gouilleux‐Gruart, V.; Feng, Y.; Dimitrov, D.; Guyétant, S.; Berthon, P. Journal: British journal of dermatology Issue: Volume 186:Number 2(2022) Page Start: 295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗